Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

See images of another tiny display with pixels the size of a human hair.

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A combination of imaging techniques reveals how herpes simplex virus type 1 assembles within infected cells, highlighting the roles of essential viral proteins in viral assembly and exit.

African giant pouched rats like Carolina prevented nearly 400,000 new cases of a deadly disease. It's possible because of ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

A preliminary study has found that efavirenz — a non-nucleoside inhibitor of HIV virus that is used for treating HIV/AIDS — can be repurposed for the treatment of chikungunya. Currently ...

Survey data suggests that over a third of organizations that relied on US funding for HIV services had already closed by ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term protection. If this yearly injection is approved and widely implemented ...

Researchers assessed epidemiologic trends of incident hepatitis C virus infection among patients with HIV infection engaged in care in the US.

Among the signatories was French scientist Francoise Barre-Sinoussi, who won a 1983 medicine Nobel prize for her work identifying the HIV virus. The US government has said the funding cuts were ...